Conmed

CNMD · NYSE

$47.58+$1.53 (+3.32%)TodayMarket closed · Oct 20, 7:00 PM ET

Prev close $46.05

CNMD analyst rating

HoldConsensus of 7 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold6
Underperform1
Sell0

12-month price target · 8 analysts

Average $46.51 (−2.2% downside)

Low: $43.43
Now: $47.58
High: $51.45

Upgrades and downgrades

The latest rating actions, newest first

CNMD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Jul 30, 2026	Maintains	Neutral	$39.00 → $45.00	43%
Wells Fargo	Jul 30, 2026	Maintains	Equal-Weight	$39.00 → $46.00	54%
BMO Capital	Jul 9, 2026	Initiates	Market Perform	$36.00	—
B of A Securities	Jun 29, 2026	Downgrade	Neutral → Underperform	$40.00	45%
B of A Securities	May 18, 2026	Maintains	Neutral	$52.00 → $40.00	45%
Wells Fargo	May 1, 2026	Maintains	Equal-Weight	$42.00 → $39.00	54%
JP Morgan	Apr 30, 2026	Maintains	Neutral	$43.00 → $40.00	56%
Piper Sandler	Mar 17, 2026	Downgrade	Overweight → Neutral	$55.00 → $39.00	43%
Wells Fargo	Jan 29, 2026	Maintains	Equal-Weight	$41.00 → $42.00	45%
Needham	Jan 29, 2026	Maintains	Hold	—	45%

The case for and against

Updated Jan 19, 2026

Bull case

Conmed Corp has demonstrated notable growth in its high-potential segments, particularly with the recent success of the BioBrace, which is expected to further bolster revenue following its full release in the third quarter of 2025. The dual-digit growth observed in the Foot & Ankle category, despite supply constraints, indicates a potential easing of these issues and reflects a resilient demand for the company's products. Management's cautious revenue guidance reinforces the company’s commitment to a sustainable top-line turnaround, further supporting a positive outlook for Conmed's financial performance.

Bear case

Conmed Corp has experienced a 27% decline in its stock year-to-date, indicating significant challenges in its turnaround efforts. The company faces ongoing capital weakness, particularly in international markets, which can be attributed to difficult year-over-year comparisons rather than an overall slowdown in hospital capital budgets. This situation has led to a revision of the price target, reflecting the company's struggles amidst a backdrop of intensified competitive pressures and operational challenges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.